{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:38:00Z","timestamp":1790293080601,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01294"],"award-info":[{"award-number":["PI21\/01294"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01294"],"award-info":[{"award-number":["PI21\/01294"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01294"],"award-info":[{"award-number":["PI21\/01294"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01294"],"award-info":[{"award-number":["PI21\/01294"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01294"],"award-info":[{"award-number":["PI21\/01294"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01294"],"award-info":[{"award-number":["PI21\/01294"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013941","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red Diabetes y Enfermedades Metab\u00f3licas Asociadas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013941","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cerca Programme, Generalitat de Catalunya, Spain"},{"DOI":"10.13039\/501100023561","name":"Ministerio de Universidades","doi-asserted-by":"publisher","award":["FPU19\/04610"],"award-info":[{"award-number":["FPU19\/04610"]}],"id":[{"id":"10.13039\/501100023561","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-024-02531-5","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T14:15:21Z","timestamp":1733321721000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["ApoC-III proteoforms are associated with better lipid, inflammatory, and glucose profiles independent of total apoC-III"],"prefix":"10.1186","volume":"23","author":[{"given":"Pere","family":"Rehues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefa","family":"Girona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Guardiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Ozcariz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N\u00faria","family":"Amig\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roser","family":"Rosales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaiza","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Ban\u00fas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Gavald\u00e0-Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonz\u00e1lez-Lle\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Rojo-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Ribalta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"issue":"July","key":"2531_CR1","first-page":"1","volume":"11","author":"J Bor\u00e9n","year":"2020","unstructured":"Bor\u00e9n J, Packard CJ, Taskinen MR. The roles of ApoC-III on the metabolism of Triglyceride-Rich Lipoproteins in humans. Front Endocrinol (Lausanne). 2020;11:1\u201310.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2531_CR2","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S0022-2275(20)31574-1","volume":"42","author":"H Campos","year":"2001","unstructured":"Campos H, Perlov D, Khoo C, Sacks FM. Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia. J Lipid Res. 2001;42(8):1239\u201349.","journal-title":"J Lipid Res"},{"issue":"1","key":"2531_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1307095","volume":"371","author":"J Crosby","year":"2014","unstructured":"Crosby J, Peloso GM, Auer PL, Crosslin DR, Stitziel NO, Lange LA, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1):22\u201331.","journal-title":"N Engl J Med"},{"issue":"1","key":"2531_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB J\u00f8rgensen","year":"2014","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32\u201341.","journal-title":"N Engl J Med"},{"key":"2531_CR5","doi-asserted-by":"crossref","unstructured":"Sacks FM, Alaupovic P, Moye LA, Cole TG, Sussex B, Stampfer MJ, Apolipoproteins VLDL et al. B, CIII, and E, and Risk of recurrent coronary events in the cholesterol and recurrent events (CARE) Trial [Internet]. 102, Circulation. 2000. http:\/\/www.circulationaha.org","DOI":"10.1161\/01.CIR.102.16.1886"},{"issue":"8","key":"2531_CR6","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1172\/JCI86610","volume":"126","author":"PLSM Gordts","year":"2016","unstructured":"Gordts PLSM, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, et al. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest. 2016;126(8):2855\u201366.","journal-title":"J Clin Invest"},{"key":"2531_CR7","doi-asserted-by":"crossref","unstructured":"Mendivil CO, Zheng C, Furtado J, Lel J, Sacks FM. Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol [Internet]. 2010 [cited 2024 Mar 21];30(2):239\u201345. https:\/\/pubmed.ncbi.nlm.nih.gov\/19910636\/","DOI":"10.1161\/ATVBAHA.109.197830"},{"issue":"31","key":"2531_CR8","doi-asserted-by":"publisher","first-page":"27769","DOI":"10.1074\/jbc.M110.203679","volume":"286","author":"W Qin","year":"2011","unstructured":"Qin W, Sundaram M, Wang Y, Zhou H, Zhong S, Chang CC, et al. Missense mutation in APOC3 within the C-terminal lipid binding domain of human ApoC-III results in impaired assembly and secretion of triacylglycerol-rich very low density lipoproteins: evidence that ApoC-III plays a major role in the formation of lipid precursors within the microsomal lumen. J Biol Chem. 2011;286(31):27769\u201380.","journal-title":"J Biol Chem"},{"issue":"20","key":"2531_CR9","doi-asserted-by":"publisher","first-page":"E2611","DOI":"10.1073\/pnas.1423849112","volume":"112","author":"K \u00c5vall","year":"2015","unstructured":"\u00c5vall K, Ali Y, Leibiger IB, Leibiger B, Moede T, Paschen M, et al. Apolipoprotein CIII links islet insulin resistance to \u03b2-cell failure in diabetes. Proc Natl Acad Sci USA. 2015;112(20):E2611\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"27","key":"2531_CR10","doi-asserted-by":"publisher","first-page":"10090","DOI":"10.1073\/pnas.0403551101","volume":"101","author":"L Juntti-Berggren","year":"2004","unstructured":"Juntti-Berggren L, Refai E, Appelskog I, Andersson M, Imreh G, Dekki N, et al. Apolipoprotein CIII promotes Ca2+-dependent beta cell death in type 1 diabetes. Proc Natl Acad Sci USA. 2004;101(27):10090\u20134.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2531_CR11","doi-asserted-by":"publisher","unstructured":"Tao Y, Xiong Y, Wang H, Chu S, Zhong R, Wang J et al. APOC3 induces endothelial dysfunction through TNF-\u03b1 and JAM-1. Lipids Health Dis [Internet]. 2016;15(1):1\u20138. https:\/\/doi.org\/10.1186\/s12944-016-0326-0","DOI":"10.1186\/s12944-016-0326-0"},{"issue":"1","key":"2531_CR12","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41590-019-0548-1","volume":"21","author":"S Zewinger","year":"2020","unstructured":"Zewinger S, Reiser J, Jankowski V, Alansary D, Hahm E, Triem S, et al. Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation. Nat Immunol. 2020;21(1):30\u201341.","journal-title":"Nat Immunol"},{"issue":"9","key":"2531_CR13","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.2337\/db09-0206","volume":"58","author":"A Hiukka","year":"2009","unstructured":"Hiukka A, St\u00e5hlman M, Pettersson C, Levin M, Adiels M, Teneberg S, et al. ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes. 2009;58(9):2018\u201326.","journal-title":"Diabetes"},{"issue":"2","key":"2531_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/0304-4165(78)90396-3","volume":"541","author":"P Vaith","year":"1978","unstructured":"Vaith P, Assmann G, Uhlenbruck G. Characterization of the oligosaccharide side chain of apolipoprotein C-III from human plasma very low density lipoproteins. BBA - Gen Subj. 1978;541(2):234\u201340.","journal-title":"BBA - Gen Subj"},{"issue":"12","key":"2531_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0144138","volume":"10","author":"HN Yassine","year":"2015","unstructured":"Yassine HN, Trenchevska O, Ramrakhiani A, Parekh A, Koska J, Walker RW, et al. The association of human apolipoprotein C-III sialylation proteoforms with plasma triglycerides. PLoS ONE. 2015;10(12):1\u201314.","journal-title":"PLoS ONE"},{"key":"2531_CR16","doi-asserted-by":"crossref","unstructured":"Koska J, Phd M, Yassine Md H, Phd OT, Phd SS, Schwenke Phd DC et al. Disialylated Apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and Type 2 diabetes. J Lipid Res. 2016;57(October 2015).","DOI":"10.1194\/jlr.P064816"},{"key":"2531_CR17","doi-asserted-by":"publisher","unstructured":"Mendoza S, Trenchevska O, King SM, Nelson RW, Nedelkov D, Krauss RM et al. Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions. J Clin Lipidol [Internet]. 2017;11(1):224\u2013233.e2. https:\/\/doi.org\/10.1016\/j.jacl.2016.12.009","DOI":"10.1016\/j.jacl.2016.12.009"},{"issue":"10","key":"2531_CR18","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1161\/ATVBAHA.119.312723","volume":"39","author":"NC Kegulian","year":"2019","unstructured":"Kegulian NC, Ramms B, Horton S, Trenchevska O, Nedelkov D, Graham MJ, et al. ApoC-III glycoforms are differentially cleared by hepatic TRL (triglyceride-Rich lipoprotein) receptors. Arterioscler Thromb Vasc Biol. 2019;39(10):2145\u201356.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2531_CR19","doi-asserted-by":"crossref","unstructured":"Kiani\u010dkov\u00e1 K, Pakanov\u00e1 Z, Kv\u011bto\u0148 F, Holazov\u00e1 A, Kundalia PH, Bar\u00e1th P et al. O-glycoprofiling of serum apolipoprotein C-III in Colorectal Cancer. Front Bioscience - Landmark. 2024;29(1).","DOI":"10.31083\/j.fbl2901032"},{"key":"2531_CR20","doi-asserted-by":"publisher","unstructured":"Sinari S, Koska J, Hu Y, Furtado J, Jensen MK, Budoff MJ et al. ApoC-III Proteoforms, plasma lipids, and cardiovascular risk in MESA. Arterioscler Thromb Vasc Biol [Internet]. 2023; https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/ATVBAHA.123.319035","DOI":"10.1161\/ATVBAHA.123.319035"},{"key":"2531_CR21","doi-asserted-by":"crossref","unstructured":"Koska J, Hansen S, Hu Y, Jensen MC, Billheimer D, Nedelkov D et al. Relationship of apolipoprotein C-III proteoform composition with ankle-brachial index and peripheral artery disease in the multi-ethnic study of atherosclerosis (MESA). Atherosclerosis. 2024;395.","DOI":"10.1016\/j.atherosclerosis.2024.117584"},{"issue":"3","key":"2531_CR22","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0022-2275(20)32459-7","volume":"40","author":"PV Bondarenko","year":"1999","unstructured":"Bondarenko PV, Cockrill SL, Watkins LK, Cruzado ID, Macfarlane RD. Mass spectral study of polymorphism of the apolipoproteins of very low density lipoprotein. J Lipid Res. 1999;40(3):543\u201355.","journal-title":"J Lipid Res"},{"key":"2531_CR23","doi-asserted-by":"crossref","unstructured":"Nicolardi S, Burgt YEM, Van Der, Dragan I, Hensbergen PJ, Deelder AM. Identification of new apolipoprotein-CIII glycoforms with ultrahigh resolution MALDI-FTICR Mass Spectrometry of Human Sera. J Proteome Res. 2013.","DOI":"10.1021\/pr400136p"},{"issue":"1","key":"2531_CR24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s00125-011-2336-9","volume":"55","author":"F Soriguer","year":"2012","unstructured":"Soriguer F, Goday A, Bosch-Comas A, Bordi\u00fa E, Calle-Pascual A, Carmena R, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia. 2012;55(1):88\u201393.","journal-title":"Diabetologia"},{"issue":"6","key":"2531_CR25","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3945\/jn.110.135566","volume":"141","author":"H Schr\u00f6der","year":"2011","unstructured":"Schr\u00f6der H, Fit\u00f3 M, Estruch R, Mart\u00ednez-Gonz\u00e1lez MA, Corella D, Salas-Salvad\u00f3 J, et al. A short screener is valid for assessing mediterranean diet adherence among older Spanish men and women. J Nutr. 2011;141(6):1140\u20135.","journal-title":"J Nutr"},{"key":"2531_CR26","doi-asserted-by":"crossref","unstructured":"Mallol R, Amigo N, Rodriguez MA, Heras M, Vinaixa M, Plana N et al. Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy. J Lipid Res. 2015.","DOI":"10.1016\/j.atherosclerosis.2014.05.647"},{"issue":"11","key":"2531_CR27","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1021\/acs.jproteome.9b00528","volume":"18","author":"R Fuertes-Mart\u00edn","year":"2019","unstructured":"Fuertes-Mart\u00edn R, Moncayo S, Insenser M, Mart\u00ednez-Garc\u00eda M\u00c1, Luque-Ram\u00edrez M, Grau NA, et al. Glycoprotein A and B height-to-width ratios as obesity-independent novel biomarkers of low-Grade chronic inflammation in women with polycystic ovary syndrome (PCOS). J Proteome Res. 2019;18(11):4038\u201345.","journal-title":"J Proteome Res"},{"key":"2531_CR28","doi-asserted-by":"crossref","unstructured":"Mallagaray A, Rudolph L, Lindloge M, M\u00f6lbitz J, Thomsen H, Schmelter F et al. Towards a precise NMR quantification of acute phase inflammation proteins from human serum. Angewandte Chemie - Int Ed. 2023;62(35).","DOI":"10.1002\/anie.202306154"},{"key":"2531_CR29","doi-asserted-by":"crossref","unstructured":"Amig\u00f3 N, Fuertes-Mart\u00edn R, Malo AI, Plana N, Ibarretxe D, Girona J et al. Glycoprotein Profile measured by a1 H-Nuclear magnetic resonance based on approach in patients with diabetes: a New Robust Method to assess inflammation. Life. 2021;11(12).","DOI":"10.3390\/life11121407"},{"key":"2531_CR30","doi-asserted-by":"crossref","unstructured":"Haffner SM. Management of dyslipidemia in adults with diabetes [Internet]. http:\/\/diabetesjournals.org\/care\/article-pdf\/21\/1\/160\/585066\/21-1-160.pdf","DOI":"10.2337\/diacare.21.1.160"},{"key":"2531_CR31","doi-asserted-by":"crossref","unstructured":"Taskinen MR, Bj\u00f6rnson E, Kahri J, S\u00f6derlund S, Matikainen N, Porthan K et al. Effects of evolocumab on the postprandial kinetics of apo (apolipoprotein) B100- and B48-Containing lipoproteins in subjects with type 2 diabetes. Arterioscler Thromb Vasc Biol. 2021;(February):962\u201375.","DOI":"10.1161\/ATVBAHA.120.315446"},{"issue":"4","key":"2531_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.arteri.2022.11.001","volume":"35","author":"JA Quesada","year":"2023","unstructured":"Quesada JA, Bertomeu-Gonz\u00e1lez V, Orozco-Beltr\u00e1n D, Cordero A, Gil-Guill\u00e9n VF, L\u00f3pez-Pineda A, et al. The benefits of measuring the size and number of lipoprotein particles for cardiovascular risk prediction: a systematic review and meta-analysis. Clin e Investigacion en Arterioscler. 2023;35(4):165\u201377.","journal-title":"Clin e Investigacion en Arterioscler"},{"key":"2531_CR33","doi-asserted-by":"crossref","unstructured":"Reiner \u017d. Hypertriglyceridaemia and risk of coronary artery disease. Nature Reviews Cardiology. Volume 14. Nature Publishing Group; 2017. pp. 401\u201311.","DOI":"10.1038\/nrcardio.2017.31"},{"issue":"May","key":"2531_CR34","first-page":"1","volume":"9","author":"D Demus","year":"2021","unstructured":"Demus D, Naber A, Dotz V, Jansen BC, Bladergroen MR, Nouta J, et al. Large-scale analysis of Apolipoprotein CIII glycosylation by ultrahigh resolution mass spectrometry. Front Chem. 2021;9(May):1\u20139.","journal-title":"Front Chem"},{"issue":"50","key":"2531_CR35","doi-asserted-by":"publisher","first-page":"31348","DOI":"10.1074\/jbc.272.50.31348","volume":"272","author":"CJ Mann","year":"1997","unstructured":"Mann CJ, Troussard AA, Yen FT, Hannouche N, Najib J, Fruchart JC, et al. Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor. J Biol Chem. 1997;272(50):31348\u201354.","journal-title":"J Biol Chem"},{"issue":"6","key":"2531_CR36","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1194\/jlr.M500455-JLR200","volume":"47","author":"JF Mauger","year":"2006","unstructured":"Mauger JF, Couture P, Bergeron N, Lamarche B. Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism. J Lipid Res. 2006;47(6):1212\u20138.","journal-title":"J Lipid Res"},{"key":"2531_CR37","doi-asserted-by":"crossref","unstructured":"Kontush A. HDL particle number and size as predictors of cardiovascular disease. Front Pharmacol. 2015;6(OCT).","DOI":"10.3389\/fphar.2015.00218"},{"issue":"11","key":"2531_CR38","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1111\/dom.15224","volume":"25","author":"R Li","year":"2023","unstructured":"Li R, Chen JX, Lu Q, Geng TT, Xia PF, Wang Y, et al. Associations of lipoprotein subclasses with risk of all-cause and cardiovascular disease mortality in individuals with type 2 diabetes: a prospective cohort study. Diabetes Obes Metab. 2023;25(11):3259\u201367.","journal-title":"Diabetes Obes Metab"},{"key":"2531_CR39","doi-asserted-by":"crossref","unstructured":"Rehues P, Girona J, Guardiola M, Plana N, Scicali R, Piro S et al. PCSK9 Inhibitors Have Apolipoprotein C-III-Related Anti-Inflammatory Activity, Assessed by 1H-NMR Glycoprotein Profile in Subjects at High or very High Cardiovascular Risk. Int J Mol Sci [Internet]. 2023 Feb 1 [cited 2024 Feb 24];24(3). https:\/\/pubmed.ncbi.nlm.nih.gov\/36768645\/","DOI":"10.3390\/ijms24032319"},{"issue":"2","key":"2531_CR40","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1161\/HYPERTENSIONAHA.122.20137","volume":"80","author":"N Andreychuk","year":"2023","unstructured":"Andreychuk N, Llop D, Moreno-Vedia J, Girona J, Ibarretxe D, Rodriguez-Borjabad C, et al. Glycoprotein serum concentrations assessed by 1H-NMR are increased in patients with high blood pressure. Hypertension. 2023;80(2):460\u20139.","journal-title":"Hypertension"},{"key":"2531_CR41","doi-asserted-by":"crossref","unstructured":"Moreno-Vedia J, Rosales R, Ozcariz E, Llop D, Lahuerta M, Benavent M et al. Triglyceride-Rich lipoproteins and glycoprotein A and B assessed by 1H-NMR in metabolic-associated fatty liver disease. Front Endocrinol (Lausanne). 2022;12.","DOI":"10.3389\/fendo.2021.775677"},{"issue":"7","key":"2531_CR42","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1373\/clinchem.2016.255828","volume":"62","author":"DA Duprez","year":"2016","unstructured":"Duprez DA, Otvos J, Sanchez OA, Mackey RH, Tracy R, Jacobs DR. Comparison of the predictive value of GlycA and other biomarkers of inflammation for total death, incident cardiovascular events, noncardiovascular and noncancer inflammatory-related events, and total cancer events. Clin Chem. 2016;62(7):1020\u201331.","journal-title":"Clin Chem"},{"issue":"6","key":"2531_CR43","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1161\/ATVBAHA.115.305635","volume":"35","author":"AO Akinkuolie","year":"2015","unstructured":"Akinkuolie AO, Pradhan AD, Buring JE, Ridker PM, Mora S. Novel protein glycan side-chain biomarker and risk of Incident Type 2 diabetes Mellitus. Arterioscler Thromb Vasc Biol. 2015;35(6):1544\u201350.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"32","key":"2531_CR44","doi-asserted-by":"publisher","first-page":"16036","DOI":"10.1073\/pnas.1902902116","volume":"116","author":"K Kawanishi","year":"2019","unstructured":"Kawanishi K, Dhar C, Do R, Varki N, Gordts PLSM, Varki A. Human species-specific loss of CMP-N-acetylneuraminic acid hydroxylase enhances atherosclerosis via intrinsic and extrinsic mechanisms. Proc Natl Acad Sci USA. 2019;116(32):16036\u201345.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2531_CR45","doi-asserted-by":"crossref","unstructured":"Reganon E, Vila V, Mart\u00ednez-Sales V, Vay\u00e1 A, Mira Y, Ferrando F et al. Sialic acid is an inflammation marker associated with a history of deep vein thrombosis. Thromb Res [Internet]. 2007 [cited 2023 Jul 14];119(1):73\u20138. https:\/\/pubmed.ncbi.nlm.nih.gov\/16500696\/","DOI":"10.1016\/j.thromres.2005.12.017"},{"issue":"13","key":"2531_CR46","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1161\/CIRCULATIONAHA.117.031139","volume":"137","author":"L Zhang","year":"2018","unstructured":"Zhang L, Wei TT, Li Y, Li J, Fan Y, Huang FQ, et al. Functional Metabolomics characterizes a key role for N-Acetylneuraminic acid in coronary artery diseases. Circulation. 2018;137(13):1374\u201390.","journal-title":"Circulation"},{"issue":"10","key":"2531_CR47","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.3390\/ijms25105365","volume":"25","author":"A Naber","year":"2024","unstructured":"Naber A, Demus D, Slieker RC, Nicolardi S, Beulens JWJ, Elders PJM, et al. Apolipoprotein-CIII O-Glycosylation is Associated with Micro- and macrovascular complications of type 2 diabetes. Int J Mol Sci. 2024;25(10):5365.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2531_CR48","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.atherosclerosis.2015.04.793","volume":"240","author":"OV Savinova","year":"2015","unstructured":"Savinova OV, Fillaus K, Harris WS, Shearer GC. Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol. Atherosclerosis. 2015;240(2):520\u20135.","journal-title":"Atherosclerosis"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02531-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02531-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02531-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T15:03:36Z","timestamp":1733324616000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02531-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2531"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02531-5","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"17 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was carried out in accordance with the Declaration of Helsinki (WHO 2011) of the World Medical Association. Written informed consent was obtained from all the participants. The study was approved by the Ethics and Clinical Investigation Committee of the Hospital Regional Universitario de M\u00e1laga (Malaga, Spain) in addition to other regional ethics and clinical investigation committees all over Spain.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"N.A. is a stock owner of Biosfer Teslab and has a patent on the method for lipoprotein profiling described in the present manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"433"}}